Clinical trials: Early Triple-Negative Breast Cancer
TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
CtDNA Based MRD Testing for NAC Monitoring in TNBC
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant…
- Trial name
- B-STRONGER-I (NCT06230185)
- Where
- 14 sites in United States
- Volunteers
- 422 people
- Sponsor
- Personalis Inc.
Triple Negative Breast Cancer, Blood and Image Guided
Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial
To learn whether certain blood and imaging tests can show which people with early-stage TNBC may already have had a complete response to chemotherapy before they go to surgery.
- Conditions
- Triple Negative Breast Cancer, Blood and Image Guided, Optimization of Neoadjuvant Therapy, Phase 2
- Trial name
- NCT07610525
- Testing
- Paclitaxel + Carboplatin, Pembrolizumab
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Triple Negative Breast Cancer
TNBC Gut Microbiota During Neoadjuvant Treatment
The gut microbiome is made up of the microbes (such as bacteria, viruses, and other organisms too small to see with the naked eye) that live in the digestive tract and has been shown to be important in metabolizing food…
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma
- Trial name
- NCT06610097
- Testing
- Nutritional Counseling
- Where
- United States
- Sponsor
- Scripps Health
Breast Cancer, Triple-negative Breast Cancer
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
TNBC is a heterogeneous disease with distinct pathological, genetic, and clinical features among subtypes. Treatment results for high-risk primary TNBC remain poor compared to other breast cancer subtypes.
- Trial name
- ADAPT-TN-IV (NCT07178730)
- Testing
- Sacituzumab govitecan, Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA], SoC Chemotherapy
- Where
- 26 sites in Germany
- Volunteers
- 765 people
- Sponsor
- Women's Cancer Study Group GmbH
Cancer, Breast, Triple Negative Breast Cancer
VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study
Background: Despite improvements in the treatment of Triple Negative Breast Cancer (TNBC), the cancer returns in half of the women and shockingly 40% are dead within 5 years of their initial cancer diagnosis.
- Conditions
- Cancer, Breast, Triple Negative Breast Cancer, Early-stage Breast Cancer
- Trial name
- NCT06409221
- Testing
- Non-interventional study, Observational only
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Concr
Breast Cancer
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
The purpose of this study is to determine the impact of pre-operative cryoablation, and immune checkpoint inhibition (ICI) on on 3-year Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative…
- Trial name
- NCT03546686
- Testing
- Pembrolizumab, Core Biopsy/Cryoablation, Breast Surgery
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- University of Texas Southwestern Medical Center
Triple Negative Breast Cancer
Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients
This study is to evaluate the efficacy and safety for dose-dense epirubicin hydrochloride with cyclophosphamide followed by nanoparticlealbumin-bound paclitaxel with PD-1 in neoadjuvant therapy for patients with triple-negative…
- Trial name
- NeoTENNIS (NCT04418154)
- Testing
- epirubicin hydrochloride, Cyclophosphamide, Albumin bound paclitaxel
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Fudan University
Triple-negative Breast Cancer (TNBC)
Predicting Response to Immunochemotherapy in Early Triple Negative Breast Cancer
The goal of this clinical trial is to identify cellular and molecular determinants of response to neoadjuvant immunochemotherapy in women aged 18 or older with early-stage triple-negative breast cancer (TNBC).
- Trial name
- PRIME-TNBC (NCT07570524)
- Testing
- Additionnal breast biospy and blood sample
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Center Eugene Marquis
Triple Negative Breast Cancer
Survival Analysis of Early Triple Negative Breast Cancer (TNBC) Women Treated With Dose Dense Sequential Adjuvant Chemotherapy
Breast cancer remains the most commonly occurring cancer and leading cause of cancer death in women worldwide. According to specific clinical, molecular and genetic characteristics of patients, breast cancer is distinguished into…
- Trial name
- NCT07820228
- Where
- Greece
- Volunteers
- 3,648 people
- Sponsor
- Hellenic Cooperative Oncology Group
Breast Cancer
A Window-of-opportunity Study of Pelareorep in Early Breast Cancer
The purpose of this study is to find out if pelareorep in combination with different therapies helps to reduce the growth of breast cancer cells and increase the immune system's response to cancer.
- Trial name
- AWARE-1 (NCT04102618)
- Testing
- Pelareorep, Letrozole, Atezolizumab
- Where
- 14 sites in Spain
- Volunteers
- 26 people
- Sponsor
- Oncolytics Biotech
Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
This study tests a new treatment approach for people with early-stage triple negative breast cancer whose tumors have a high number of immune cells, called tumor-infiltrating lymphocytes or TILs, as seen by a pathologist on…
- Trial name
- NeoTILs (NCT07743190)
- Testing
- Carboplatin, Paclitaxcel, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Medical University of South Carolina
Breast Cancer, Locally Advanced Breast Cancer
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
The purpose of this study is to compare a special type of mammogram that uses a contrast agent called contrast-enhanced digital mammography with contrast-enhanced digital breast tomosynthesis (CEDM+CEDBT), with breast magnetic…
- Conditions
- Breast Cancer, Locally Advanced Breast Cancer, Neoadjuvant Chemotherapy, HER2-positive Breast Cancer
- Trial name
- NCT06220214
- Testing
- CEDM, CEDBT, Omnipaque 350mgI/mL Solution for Injection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alison Stopeck
Metastatic Triple Negative Breast Cancer
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
The study hypothesise that the combination of carboplatin, gemcitabine, bevacizumab and atezolizumab may be synergistic and improve outcomes for patients with early relapsed TNBC by overcoming mechanisms of immune resistance and…
- Trial name
- BELLA (NCT04739670)
- Testing
- Atezolizumab, Bevacizumab, Gemcitabine
- Where
- 4 sites in Australia
- Volunteers
- 31 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Breast Cancer
A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer: A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and…
- Trial name
- COMPASS-TNBC (NCT06508216)
- Testing
- Dato-DXd, Durvalumab
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Triple Negative Breast Cancer
CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)
This is an open-label, randomized, window-of-opportunity phase 2 clinical study evaluating the biological activity of preoperative Stereotactic Body RadioTherapy (SBRT) alone (Arm 1), and combined with subcutaneous (SC) followed…
- Trial name
- NCT04807192
- Testing
- stereotactic body radiotherapy, CMP-001
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Breast Cancer, TNBC - Triple-Negative Breast Cancer
To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer
To investigate the efficacy and safety of terbinumab combined with chemotherapy (epirubicin + cyclophosphamide → nab-paclitaxel + carboplatin) in neoadjuvant therapy of triple-negative breast cancer after HIFU.
- Trial name
- HIFU (NCT05491694)
- Testing
- Toripalimab, Epirubicin, High Intensity Focused Ultrasoun
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Triple Negative Breast Cancer
Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer
The purpose of this study is to increase survival of patients with early and locally advanced triple-negative breast cancer adding selumatinib to standard preoperative chemotherapy regimen.
- Trial name
- NCT02685657
- Testing
- Drug: Selumetinib, Doxorubicin, Cyclophosphamide
- Volunteers
- 164 people
- Sponsor
- Russian Academy of Medical Sciences
Triple Negative Breast Cancer
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in…
- Trial name
- NCT02032277
- Testing
- Cyclophosphamide, Doxorubicin, Paclitaxel
- Where
- 158 sites in United States, Australia and 13 more
- Volunteers
- 634 people
- Sponsor
- AbbVie
Adenocarcinoma of the Breast, Breast Cancer
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
The purpose of this study is to find out if it is practical (feasible) to give dose-dense CMF (cyclophosphamide, methotrexate, and fluorouracil) in two standard chemotherapy regimens in people with breast cancer, age 70 and older.
- Conditions
- Adenocarcinoma of the Breast, Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT07768436
- Testing
- CMF Regimen, Paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 76 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Triple Negative Breast Neoplasms
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
This is a multicenter, prospective, randomized, open-label phase II study evaluating the efficacy and safety of PO→EC as neoadjuvant treatment of operable and locally advanced breast cancer in patients with HR deficiency.
- Conditions
- Breast Cancer, Triple Negative Breast Neoplasms, HRpos Breast Neoplasms, BRCA 1 /2 and / or HRD
- Trial name
- GeparOla (NCT02789332)
- Testing
- PwO, PwCb, EC
- Where
- 12 sites in Germany
- Volunteers
- 107 people
- Sponsor
- GBG Forschungs GmbH